Upload Records Snowball Search Search OpenAlex
About the database ScholarIQanswers from OpenAlex & ORCID
How has Dirk Winkler's publication output changed over time?
ScholarIQpublication output · 2007–2023
Output grew0% over the shown period — from 1 works in 2007 to 1 in 2023.
1
2
1
3
1
1
1
1
20072008200920102011201220142023
What are the most-cited papers on Dirk Winkler?
ScholarIQmost cited works
Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial
Michael Hallek, Kirsten Fischer, Guenter Fingerle-Rowson, AM Fink, R. Busch, Jiřı́ Mayer, M. Hensel, Georg Hopfinger, G Hess, Ulrich von Grünhagen, Michèle Bergmann, J. Catalano, Pier Luigi Zinzani, Federico Caligaris‐Cappio, JF Seymour, A Berrébi, Ulrich Jäger, Bruno Cazin, Marek Trněný, Anne Westermann, C-M Wendtner, BF Eichhorst, Peter Staib, Andreas Bühler, Dirk Winkler, Thorsten Zenz, Sebastian Böttcher, Matthias Ritgen, Myriam Mendila, Michael Kneba, Hartmut Döhner, S. Stilgenbauer
The Lancet. 20101,874 Citations
<i>TP53</i> Mutation and Survival in Chronic Lymphocytic Leukemia
Thorsten Zenz, Barbara Eichhorst, Raymonde Busch, Tina Denzel, Sonja Häbe, Dirk Winkler, Andreas Bühler, Jennifer Edelmann, Manuela Bergmann, Georg Hopfinger, Manfred Hensel, Michael Hallek, Hartmut Döhner, Stephan Stilgenbauer
Journal of Clinical Oncology. 2010597 CitationsOPEN ACCESS
Gene mutations and treatment outcome in chronic lymphocytic leukemia: results from the CLL8 trial
Stephan Stilgenbauer, Andrea Schnaiter, Peter Paschka, Thorsten Zenz, Marianna Rossi, Konstanze Döhner, Andreas Bühler, Sebastian Böttcher, Matthias Ritgen, Michael Kneba, Dirk Winkler, Eugen Tausch, Patrick Hoth, Jennifer Edelmann, Daniel Mertens, Lars Bullinger, Manuela Bergmann, Sabrina Kless, Silja Mack, Ulrich Jäger, Nancy Patten, Lin Wu, Michael Wenger, Günter Fingerle‐Rowson, Peter Lichter, Mario Cazzola, Clemens‐Martin Wendtner, Anna Maria Fink, Kirsten Fischer, Raymonde Busch, Michael Hallek, Hartmut Döhner
Blood. 2014509 Citations
Bendamustine in Combination With Rituximab for Previously Untreated Patients With Chronic Lymphocytic Leukemia: A Multicenter Phase II Trial of the German Chronic Lymphocytic Leukemia Study Group
Kirsten Fischer, Paula Cramer, Raymonde Busch, Sebastian Böttcher, Jasmin Bahlo, Jöerg Schubert, Karl Heinz Pflüger, Silke Schott, Valentin Goede, Susanne Isfort, Julia von Tresckow, Anna‐Maria Fink, Andreas Bühler, Dirk Winkler, Karl‐Anton Kreuzer, Peter Staib, Matthias Ritgen, Michael Kneba, Hartmut Döhner, Barbara Eichhorst, Michael Hallek, Stephan Stilgenbauer, Clemens‐Martin Wendtner
Journal of Clinical Oncology. 2012433 CitationsOPEN ACCESS
Monoallelic TP53 inactivation is associated with poor prognosis in chronic lymphocytic leukemia: results from a detailed genetic characterization with long-term follow-up
Thorsten Zenz, Alexander Kröber, Katrin Scherer, Sonja Häbe, Andreas Bühler, Axel Benner, Tina Denzel, Dirk Winkler, Jennifer Edelmann, Carsten Schwänen, Hartmut Döhner, Stephan Stilgenbauer
Blood. 2008381 CitationsOPEN ACCESS
Related on ScholarIQ
Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial
Paper
<i>TP53</i> Mutation and Survival in Chronic Lymphocytic Leukemia
Paper
Gene mutations and treatment outcome in chronic lymphocytic leukemia: results from the CLL8 trial
Paper
Bendamustine in Combination With Rituximab for Previously Untreated Patients With Chronic Lymphocytic Leukemia: A Multicenter Phase II Trial of the German Chronic Lymphocytic Leukemia Study Group
Paper
Monoallelic TP53 inactivation is associated with poor prognosis in chronic lymphocytic leukemia: results from a detailed genetic characterization with long-term follow-up
Paper
Bendamustine Combined With Rituximab in Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia: A Multicenter Phase II Trial of the German Chronic Lymphocytic Leukemia Study Group
Paper